In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sinovac Biotech Ltd.

http://www.sinovac.com/

Latest From Sinovac Biotech Ltd.

Stock Watch: When Governments Step In

Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.

Stock Watch Advisory Committees

Xian Under Lockdown, mRNA Vaccines Remain Elusive In China

A relatively large outbreak in another major Chinese city after original epicenter Wuhan heightens the urgency for a more effective mRNA vaccine.

China Coronavirus COVID-19

China mRNA Player Abogen Gets $300m More As Country Eyes Omicron Threat

From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.

China Coronavirus COVID-19

Research Sheds New Light On Coronavirus Origins, Early Wuhan Cases

New research by US-based Canadian scientist Michael Worobey sheds further light on the role of the Wuhan market in the human origins of SARS-CoV-2.

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • Beijing Kexing Bioproducts
    • Sinovac Dalian Vaccine Technology Co., Ltd.
    • Sinovac (Cayman) Limited
UsernamePublicRestriction

Register